Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogenerics In Holding Pattern As Legislation And Election Campaigns Simmer

Executive Summary

The pending introduction of follow-on biologics legislation by Reps. Anna Eshoo, D-Calif., and Joe Barton, R-Texas, will likely help parties in the debate gauge the strength of their positions

You may also be interested in...



Most Biosimilars Would Need Clinical Trials, ASCO Tells House Panel

While urging Congress to write legislation that allows FDA to decide which scientific data are needed to approve follow-on biologics, comments from the American Society of Clinical Oncology to a House subcommittee note that clinical trials will be necessary for most FOBs

Most Biosimilars Would Need Clinical Trials, ASCO Tells House Panel

While urging Congress to write legislation that allows FDA to decide which scientific data are needed to approve follow-on biologics, comments from the American Society of Clinical Oncology to a House subcommittee note that clinical trials will be necessary for most FOBs

Editor’s Perspective: Is The Ketek Scandal Good For Big Pharma? Generic Biologic Bill Could Suffer

It was not a pretty sight in Room 2123 of the Rayburn House Office Building on Feb. 12, where the House's Energy and Commerce Committee's Oversight and Investigations Subcommittee held a hearing on fraud in the studies of the antibiotic Ketek. The head of Sanofi-Aventis' U.S. R&D had to acknowledge he could not verify that other studies were free from fraud, and committee members lambasted FDA Commissioner Andrew von Eschenbach in absentia

Related Content

UsernamePublicRestriction

Register

PS049303

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel